Non-analgesic effects of opioids: Opioid-induced respiratory depression

Current Pharmaceutical Design

Volumn 18, Issue 37, 2012, Pages 5994-6004

  Boom, Merel ^a   Niesters, Marieke ^a   Sarton, Elise ^a   Aarts, Leon ^a   Smith, Terry W ^a   Dahan, Albert ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Buprenorphine; Fentanyl; Glia; Morphine; Naloxoxe; Opioid receptor; Opioid receptor agonist; Opioid receptor antagonist; Ventilatory control

Indexed keywords

AMPAKINE; BUPRENORPHINE; FENTANYL; NALOXONE; OPIATE; OPIATE RECEPTOR; PHOSPHODIESTERASE IV INHIBITOR; SEROTONIN; TOLL LIKE RECEPTOR; TRAMADOL; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ARTICLE; BRAIN STEM; CLINICAL TRIAL; DRUG EFFECT; DRUG INDUCED DISEASE; GLIA CELL; HUMAN; NONHUMAN; PONS; PRIORITY JOURNAL; RESPIRATION DEPRESSION;

ANALGESICS, OPIOID; ANIMALS; HUMANS; MICROGLIA; NALOXONE; NARCOTIC ANTAGONISTS; PAIN; RECEPTORS, OPIOID, MU; RESPIRATION; RESPIRATORY CENTER; RESPIRATORY INSUFFICIENCY; TOLL-LIKE RECEPTOR 4;

EID: 84873966543     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212803582469     Document Type: Article

References (132)

1. Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology 2010; 112: 226-38.
2. Taylor S, Kirton OC, Staff I, Kozol RA. Postoperative day one: a high risk period for respiratory events. Am J Surg 2005; 190: 752-6.
3. Lötsch J, Dudziak R, Freynhagen R, Marschner J, Geisslinger G. Fatal respiratory depression after multiple intravenous morphine injections. Clin Pharmacokinet 2006; 45: 1051-60.
4. Overdyk FJ. Postoperative opioids remain a serious patient safety threat. Anesthesiology 2010; 113: 259-60.
5. Leino K, Mildh L, Lertola K, Seppälä T, Kirvelä O. Time course of changes in breathing pattern in morphine-and oxycodone-induced respiratory depression. Anaesthesia 1999; 54: 835-40.
6. Pattinson KTS. Opioids and the control of respiration. Br J Anaesth 2008; 100: 747-58.
7. Montandon G, Qin W, Ren J, Greer JJ, Horner RL. PreBötzinger complex neurokinin-1 receptor-expressing neurons mediate opioidinduced respiratory depression. J Neurosci 2011; 31: 1291-301.
8. Martin WR. Opioid antagonists. Pharmacol Rev 1967; 19: 463-521.
9. Meunier JC, Mollereau C, Toll L, et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 1995; 377:532-5.
10. Tegeder I, Geisslinger G. Opioids as modulators of cell death and survival-unraveling mechanisms and revealing new indications. Pharmacol Rev 2004; 56: 351-69.
11. Chen YL, Law P-Y, Loh HH. The other side of the opioid story: modulation of cell growth and survival signaling. Curr Med Chem 2008; 15: 772-8.
12. Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Ann Rev Biochem 2004; 73: 953-90.
13. rd ed. New York: Prentice-Hall International Inc.1991; pp. 385-99.
14. Dahan A, Sarton E, Teppema L, et al, Anesthetic potency and influence of morphine and sevoflurane on respiration in μ-opioid receptor knockout mice. Anesthesiology 2001; 94: 824-32.
15. Romberg R, Sarton E, Teppema L, Matthes H, Kieffer B, Dahan A. No difference between morphine and morphine-6-glucuronid on respiration in μ-opioid receptor-deficient mice. Br J Anaesth 2003; 91: 862-70.
16. Aldrich JV, Vigil-Cruz SC. Narcotic analgesics. In: Abraham DJ Ed. Burger's Medicinal Chemistry and Drug Discovery vol. 6. Hoboken: Wiley, 2003: pp. 329-481.
17. Corbett AD, Henderson G, McKnight AT, Paterson SJ. 75 years of opioid research: the exciting but vain conquest for the Holy Grail. Br J Pharmacol 2006; 147 (Suppl 1): S153-62.
18. Pfeiffer A, Brantl V, Herz A, Emrich HM. Pyschotomimesis mediated by kappa opiate receptors. Science 1986; 233: 774-6.
19. Barber A, Gottschlich R. Novel developments with selective, nonpeptidic kappa-opioid receptor agonists. Exp Opin Investig Drugs 1997; 6: 1351-68.
20. Coop A, Rice KC. Role of δ-opioid receptors in biological processes. Drug News Perspect 2000; 13: 481-7.
21. Aldrich JV, McLaughlin JP. Peptide kappa opioid receptor ligands: potential for drug development. AAPS J 2009; 11: 312-22.
22. Ballet S, Pietsch M, Abell AD. Multiple ligands in opioid research. Protein Peptide Lett 2008; 15: 668-82.
23. Freye E, Schenk G. Prolonged mu-and delta-receptor occupancy may result in naloxone-reversible respiratory depression and naloxone-irreversible antinociception. Prog Clin Biol Res 1990; 328: 379-84.
24. Ling GSF, Spiegal K, Lockhart SH, Paternal GW. Separation of opioid analgesia from respiratory depression: evidence for different receptor mechanisms. J Pharm Exp Ther 1985; 232:144-55
25. Kilpatrick GH, Smith TW. Morphine-6-glucuronide: actions and mechanisms. Med Res Rev 2005; 5: 521-44.
26. Hanna MH, Elliott KM, Fung M. Randomized, double-blind study of the analgesic efficacy of morphine-6-glucuronide versus morphine sulfate for postoperative pain in major surgery. Anesthesiology 2005; 102: 815-21.
27. Thompson PI, Joel SP, John L, Wedzicha JA, Maclean M, Slevin ML. Respiratory depression following morphine and morphine-6-glucuronide in normal subjects. Br J Clin Pharmacol 1995; 40: 145-52.
28. Romberg R, Olofsen E, Sarton E, Teppema L, Dahan A. Pharmacodynamic effect of morphine-6-glucuronide versus morphine on hypoxic and hypercapnic breathing in healthy volunteers. Anesthesiology 2003; 99: 788-98.
29. Hucks D, Thompson PI, McLoughlin L, et al, Explanation at the opioid receptor level for differing toxicity of morphine and morphine-6-glucuride. Br J Cancer 1992; 65: 122-6.
30. rd ed. Br J Pharmacol 2008; 153 (Suppl 2): S1-209.
31. Lötsch J. Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manage 2005; 29 (Suppl 5): S90-103.
32. Olofsen E, van Dorp E, Teppema L, et al. Naloxone reversal of morphine-and morphine-6-glucuronide-induced respiratory depression in healthy volunteers: A mechanism-based pharmacokinetic-pharmacodynamic modeling study. Anesthesiology 2010; 112: 1417-27.
33. Boas RA, Villiger JW. Clinical actions of fentanyl and buprenorphine. The significance of receptor binding. Br J Anaesth 1985; 57: 192-6.
34. Yassen A, Olofsen E, Romberg R, et al. Mechanism-based PK/PD modeling of the respiratory depressant effects of buprenorphine and fentanyl in healthy volunteers. Clin Pharmacol Ther 2007; 81: 50-8.
35. Dahan A, Yassen A, Bijl H, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 2005; 94: 825-34.
36. Lötsch J, Skarke C, Schmidt H, Grösch S, Geisslinger G. The transfer half-life of morphine-6-glucuronide from plasma to effect site assesssed by pupil size measurement in healthy volunteers. Anesthesiology 2001; 95: 1329-38.
37. Carrupt PA, Testa B, Bechalany A, et al. Morphine-6-glucuronide and morphine-3-glucuronide as molecular chameleons with unexpected lipophilicity. J Med Chem 1991; 34: 1272-5.
38. Cowan A, Doxey JC, Harry EJ. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol 1977; 60: 547-54.
39. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994; 55: 569-80.
40. Chevillard L, Mégarbane B, Risède P, Baud FJ. Characteristics and comparative severity of respiratory response to toxic doses of fentanyl, methadone, morphine and buprenorphine in rats. Toxicol Lett 2009; 191: 327-40.
41. Budd K. High dose buprenorphine for post-operative analgesia. Anaesthesia 1981; 36: 900-3.
42. Christoph T, Kögel B, Schiene K, Méen M, De Vry J, Friderichs E. Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol 2005; 507: 87-98.
43. Budd K, Collett BJ. Old dog-new (ma)trix (editorial). Br J Anaesth 2003; 90: 722-4.
44. Tantucci C, Paoletti F, Bruni B, et al. Acute respiratory effects of sublingual buprenorphine: comparison with intramuscular morphine. Int J Clin Pharmacol Ther Toxicol 1992; 30: 202-7.
45. Pergolizzi J, Aloisi AM, Dahan A. et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract 2008; 8: 287-313.
46. Villiger JW, Taylor KM. Buprenorphine: characteristics of binding sites in the rat central nervous system. Life Sci 1981; 29: 2699-708.
47. Toll L, Berzetei-Gurske IP, Polgar WE, et al. Standard binding and functional assays relating to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr 1998;178: 440-66.
48. McCormack K, Prather P, Chapleo C. Some new insights into the effects of opioids in phasic and tonic nociceptive tests. Pain 1998; 78: 79-98.
49. Koppert W, Ihmsen H, Körber N, et al. Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain 2005;118: 15-22.
50. Le Roux PJ, Coetzee JF. Tramadol today. Curr Opin Anesthesiol 2000; 13: 457-61.
51. Budd K. The role of tramadol in acute pain management. Acute Pain 1999; 4: 189-96.
52. Budd K, Langford R. Tramadol revisited. Br J Anaesth 1999; 82: 493-5.
53. Raffa RB, Friderichs E, Reimann W, Shank RP, Vaught JL. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an "atypical" opioid analgesic. J Pharmacol Exp Ther 1992; 260: 275-85.
54. Dayer P, Collart L, Desmeules J. The pharmacology of tramadol. Drugs 1994; 47: 3-7.
55. Raffa RB. A novel approach to the pharmacology of analgesics. Am J Med 1996; 101: 40S-6S.
56. Raffa RB, Friderichs E, Reimann W, et al. Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J Pharmacol Exp Ther 1993; 267: 331-40.
57. Ide S, Minami M, Ishihara K, Uhl GR, Sora I, Ikeda K. Mu opioid receptor-dependent and independent components in effects of tramadol. Neuropharmacology 2006; 51: 651-8.
58. Stamer UM, Stüber F, Muders T, Musshoff F. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth Analg 2008; 107: 926-9.
59. Nossamen VE, Ramadhyani R, Kadowitz PJ, Nossamen BD. Advances in perioperative pain management: use of medications with dual analgesic mechanisms, tramadol and tapentadol. Anesthesiol Clin 2010; 28: 647-66.
60. Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci 2007; 10: 1361-8
61. Watkins LR, Hutchinson MR, Rice KC, Maier SV. The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci 2009; 30: 581-591.
62. Chao CC, Hu S, Shark KB, Sheng WS, Gekker G, Petersen PK. Activation of mu opioid receptors inhibits microglial cell chemotaxis. J Pharmacol Exp Ther 1997; 281: 998-1004.
63. Cao H, Zhang YQ. Spinal glial activation contributes to pathological pain states. Neurosci Biobehav Rev 2008; 32: 972-983.
64. Verge GM, Milligan ED, Maier SF, Watkins LR, Naeve GS, Foster AC. Fractaline (CX3CL1) and fractaline receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. Eur J Neurosci 2004; 20: 1150-60.
65. McGaraughty S, Chu KL, Namovic MT, et al. P2X7-related modulation of pathological nociception in rats. Neuroscience 2007; 146: 1817-28.
66. Watkins LR, Hutchinson MR, Milligan ED, Maier SF. "Listening" and "talking" to neurons: implications of immune activation for pain control and increasing the efficacy of opioids. Brain Res Rev 2007; 56: 148-69.
67. Watkins LR, Hutchinson MR, Rice, Maier SF. The "toll" of opioidinduced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol sci 2009; 30: 581-91.
68. Hutchinson MR, Bland ST, Johnson KW, Rice KC, Maier SF, Watkins LR. Opioid-induced glial activation: Mechanisms of activation and implications for opioid analgesia, dependence and reward. ScientificWorldJournal 2007; 7: 98-111.
69. Miyake K. Innate immune sensing of pathogens and danger signals by cell surface toll-like receptors. Semin Immunol 2007; 19: 3-10.
70. Hutchinson MR, Zhang Y, Shridhar M, et al. Evidence that opioids may have toll like receptor 4 and MD-2 effects. Brain Behav Immun 2010; 24: 83-95.
71. Kim D, Kim MA, Cho IH, et al. A critical role of toll-like receptor 2 in nerve injury-induced spinal cord glial cell activation and pain hypersensitivity. J Biol Chem 2007; 282: 14975-83.
72. Obata K, Katsura H, Miyoshi K, et al. Toll-like receptor 3 contributes to spinal glial activation and tactile allodynia after nerve injury. J Neurochem 2008; 105: 2249-59.
73. Angst MS, Clark JD. Opioid-induced hyperalgesia. A qualitative systemic review. Anesthesiology 2006; 104: 570-89
74. Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans. Molecular mechanisms and clinical considerations. Clin J Pain 2008; 24: 479-96.
75. Fishbain DA, Cole B, Lewis JE, Gao J, Rosomoff RS. Do opioids induce hyperalgesia in humans? An evidence-based structures review. Pain Med 2009; 10: 829-39
76. Wu HE, Thompson J, Sun HS, Terashvill M, Tseng LF. Antianalgesia; stereoselective action of dextro-morphine over levomorphine on glia in the mouse spinal cord. J Pharmacol Exp Ther 2005; 314: 1101-8.
77. Lewis SS, Hutchinson MR, Rezvani N, et al. Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like recptor 4/MD-2 and interleukin 1beta. Neuroscience 2010; 165: 569-83.
78. Hülsmann S, Oku Y, Zhang W, Richter DW. Metabolic coupling between glia and neurons is necessary for maintaining respiratory activity in transverse medullary slices of neonatal mouse. Eur J Neurosci 2000; 12: 856-62.
79. Huxtable AG, Zwicker JD, Alvares TS, et al. Glia contribute to the purinergic modulation of inspiratory rhythm-generating networks. J Neurosci 2010; 30: 3947-58.
80. 2 chemosensitivity and respiratory control. J Appl Physiol 2010; 108: 1803-11.
81. Higashimoto Y, Yamagata Y, Taya S, et al. Systemic inflammation in chronic pulmonary disease and asthma: similarities and differences. Respirology 2008; 13: 128-33.
82. Rubini A. IL-6 increases airway resistance in the rat. Cytokine 2010; 51: 266-73.
83. Longnecker DE, Grazis PA, Eggars GWN Jr. Naloxone for antagonism of morphine-induced respiratory depression. Anesth Analg 1973; 52: 447-53.
84. Johnstone RE, Jobes DR, Kennell EM, Behar MG, Smith TC. Reversal of morphine anesthesia with naloxone. Anesthesiology 1974; 41: 361-7.
85. van Dorp E, Yassen A, Sarton E, et al. Naloxone-reversal of buprenorphine-induced respiratory depression. Anesthesiology 2006; 105: 51-7.
86. Cassel JA, Daubert JD, DeHaven RN. Alvimopan binding to the micro opioid receptor: comparative binding kinetics of opioid antagonists. Eur J Pharmacol. 2005; 520: 29-36.
87. Yassen A, Olofsen E, van Dorp E, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the reversal of buprenorphine-induced respiratory depression by naloxone. Clin Pharmacokinet 2007; 46: 966-80.
88. Amin HM, Sopchak AM, Esposito BF, et al. Naloxone-induced and spontaneous reversal of depressed ventilatory responses to hypoxia during and after continuous infusion of remifentanil or alfentanil. J Pharm Exp Ther 1995; 274: 34-9.
89. Takahashi M, Sugiyama K, Hori M, Chiba S, Kusaka K. Naloxone reversal of opioid anesthesia revisited: clinical evaluation and plasma concentration analysis of continuous naloxone infusion after anesthesia with high-dose fentanyl. J Anesth 2004; 18: 1-8.
90. Gal TJ. Naloxone reversal of buprenorphine-induced respiratory depression. Clin Pharmacol Ther. 1989; 45: 66-71.
91. McGilliard KL, Takemori AE. Antagonism by naloxone of narcotic induced respiratory depression and analgesia. J Pharmacol Exp Ther 1978; 207: 494-503.
92. Vaidehi N, Kenakin T. The role of conformational ensembles of seven transmembrane receptors in functional selectivity. Curr Opin Pharmaol 2010; 10: 775-81.
93. Sanchez-Blazquez P, Gomez-Serranillos P, Garzon J. Agonists determine the pattern of G-protein activation in μ-opioid receptormediated supraspinal analgesia. Brain Res Bull 2001; 54: 229-35.
94. Pieyro G, Archer-Lahlou E. Ligand-specific receptor states: implications for opiate receptor signaling and regulation. Cell Signal 2007; 19: 8-19.
95. Hutchinson MR, Zhang Y, Brown K, et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci 2008; 28: 20-9.
96. Kim H-S, Suh Y-H. Minocycline and neurodegenerative diseases. Behav Brain Res 2009; 196: 168-79
97. Smith KS, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther 2005; 27: 1329-42.
98. Converse AK, Larsen EC, Engle JW, Barnhart TE, Nickles RJ, Duncan ID. 11C-(R)-PK11195 PET imaging of microglial activation and response to minocycline in zymosan-treated rats. J Nucl Med 2011; 52: 257-67.
99. Hutchinson MR, Northcutt AL, Chao LW, et al. minocycline suppresses morphine-induced respiratory depression, suppresses morphine-induced reward, and enhances systemic morphine-induced analgesia. Brain Behav Immun 2008; 22: 1248-56.
100. Morgado C, Pereira-Terra P, Cruz CD, Tavares I. Minocycline completely reverses mechanical hyperalgesia in diabetic rats through microglia-induced changes in the expression of potassium chloride co-transporter 2 (KCC2) at the spinal cord. Diabetes Obes Metab 2011; 13: 150-9.
101. Ledeboer A, Hutchinson MR, Watkins LR, Johnson KW. Ibudilast (AV-411): a new class therapeutic candidate for neuropathic pain and opioid withdrawal systems. Expert Opin Investig Drugs 2007; 16: 935-50.
102. Rolan P, Hutchinson M, Johnson K. Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease. Expert Opin Pharmacother 2009; 10: 2897-904.
103. Hutchinson MR, Lewis SS, Coats BD, et al. reduction of opioidwithdrawal and potentiation of acute ioioid analgesia by systemic AV411 (ibudilast). Brain Behav Immun 2009; 23: 240-50.
104. Richter DW, Manzke T, Wilken B, Ponimaskin E. Serotonin receptors: guardians of stable breathing. Trends Molec Med 2003; 12: 542-8.
105. 1A receptors. J Pharmacol Exp Ther 2000; 292: 704-13.
106. Guenther U, Manzke T, Wrigge H, et al. The counteraction of opioid-induced ventilatory depression by the serotonin 1A antagonist 8-OH-DPAT does not antagonize antinociception in rats in situ and in vivo. Anesth Analg 2009; 108: 1169-76.
107. Dutschmann M, Waki H, Manzke T, et al. The potency of different serotergic agonists in counteracting opioid evoked cardiorespiratory disturbances. Phil Trans R Soc B 2009; 364: 2611-23.
108. Wilken B, Lalley P, Bischoff AM, et al. Treatment of apneustic respiratory disturbance with a serotonin-receptor agonist. J Pediatr 1997; 130: 89-94.
109. El-Khatib MF, Kiwan RA, Jameleddine GW. Buspirone treatment for apneustic breathing in brain stem infarct. Respir Care 2003; 48: 956-8.
110. Oertel BG, Scheider A, Rohrbacher M, et al. The partial 5-hydroxytryptamine1A receptor agonist buspirone does not antagonise morphine-induced respiratory depression in humans. Clin Pharmacol Ther 2007; 81: 59-68.
111. Guenther U, Bischoff A, Kettler D, Richter DW. 5-HT1A-agonists protect against opioidergic depression of respiration. In: Urban BW, Barann M, Eds. Molecular and basic mechanisms of anesthesia. D-49525 Lengerich: Papst Science Publishers 2001; pp. 400-3.
112. 1A-R-agonist, antagonizes morphine-induced ventilatory depression in anesthetized rats. Anesth Analg 2010; 111: 901-7
113. Calabrese EJ. Horesis: basic, generalizable, central to toxicology and a method to improve risk-assessment process. Int J Occup Environ Health 2004; 10: 466-7.
114. Manzke T, Dutschmann M, Schlaf G, et al. serotonin targets inhibitory synapses to induce modulation of network functions. Phillos Trans R Soc Lond B Biol Sci 2009; 364: 2589-602.
115. Manzke T, Niebert M, Koch UR, et al. Serotonin receptor 1Amodulated phosphorylation of glycine receptor 3 controls the breathing in mice. J Clin Invest 2010; 11: 4118-28.
116. Manzke T, Guenther U, Ponimaskin EG, et al. 5-HT4(a) receptors avert opioid-induced breathing depression without loss of analgesia. Science 2003; 301: 226-9.
117. Manzke T, Preusse S, Richter DW. Developmental changes of serotonin 4(a) recepror expression in the rat pre-Bötzinger complex. J Comp Neurol 2008; 506: 775-90.
118. Meyer LCR, Fuller A, Mitchell D. Zacopride and 8-OH-DPAT reverse oioid-induced respiratory depression and hypoxia but not catatonic immobilization in goats. Am J Physiol Regul Integr Comp Physiol 2006; 290: R405-13.
119. Lötsch J, Skarke C, Schneider A, Hummel T, Geisslinger G. The 5-hydroxy-tryptamine 4 recptor agaonis mosapride does not antagonize morphine-induced respiratory depression. Clin Pharmacol ther 2005; 78: 278-87.
120. 4 receptor splice variants. Pharmacology 2010; 85: 224-33.
121. Agosti RM. 5HT1F-and 5HT7-receptor agonists for the treatment of migraines. CNS Neurol Disord Drug Targets 2007; 6: 235-7.
122. 7(a) receptor isoform coupled to adenylate cyclase stimulation. J Pharmacol Exp Ther 1998; 508-14.
123. Lynch G. Glutamate-based therapeutic approaches: AMPAKINES. Curr Opin Pharmacol 2006; 6: 82-8.
124. Greer JJ, Smith JC, Feldman JL. The role of excitatory amino acids in the generation and transmission of respiratory drive in the neonatal rat. J Physiol 1991; 437: 727-49.
125. Arai AC, Xia YF, Suzuki E. Modulation of AMPA receptor kinetics differentially influences synaptic plasticity in the hippocampus. Neurosci 2004; 123: 1011-24.
126. Ren J, Ding X, Funk GD, Greer JJ. Ampakine CX717 protects against fentanyl-induced respiratory depression and lethal apnea in rats. Anesthiology 2009; 110: 1364-70.
127. Greer JJ, Ren J. Ampakine therapy to counter fentanyl-induced respiratory depression. Resp Physiol Neurobiol 2009; 168: 153-7.
128. Oertel BG, Felden L, Tran PV, et al. Selective antagonism of opioid-induced ventilatory depression by an ampakine molecule in humans without loss of opioid analgesia. Clin Pharmacol Ther 2010; 87: 204-11.
129. Bhatia J Current options in the management of apnea of prematurity. Clin Pediatr 2000; 39: 327-36.
130. 1 receptormediated adenosine action on neuronal networks in the brainstemspinal cord of newborn rats. Neuroscience 2000; 96: 359-71.
131. Fredholm BB, Bättig K, Holmen J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999; 51: 83-133.
132. Ruangkittisakul A, Ballanyi K. Methylxanthine reversal of opioidevoked inspiratory depression via phosphodiesterase-4 blockade. Resp Physiol Neurobiol 2010; 94-105.